UNIVERSITY OF TEXAS SYSTEM; THE UNIVERSITY OF TEXAS SYSTEM;BOARD OF REGENTS
发明人:
SOTH, MICHAEL J.,JONES, PHILIP,RAY, JAMES,LIU, GANG,LE, KANG,CROSS, JASON
申请号：
CA3035195
公开号：
CA3035195A1
申请日:
2017.08.28
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy -induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).
